International Cancer Proteogenome Consortium

Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer Cancer Cell. 2026 Jan 8:S1535-6108(25)00548-3. doi: 10.1016/j.ccell.2025.12.014. International Cancer Proteogenome Consortium
PMID: 41512870

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures Cancer Cell. 2025 Jul 30:S1535-6108(25)00317-4. CPTAC and ICPC
PMID: 40749670

Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies Cancer. 2025 Jul 1;131(13):e35897. International Cancer Proteogenome Consortium
PMID: 40545870

Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers Mol Cancer. 2025 Jun 11;24(1):174. International Cancer Proteogenome Consortium
PMID: 40500697

Melanoma Proteomics Unveiled: Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT J Proteome Res. 2025 Jun 6;24(6):3117-3128. International Cancer Proteogenome Consortium
PMID: 40322912

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups Cancer Cell. 2025 Apr 1:S1535-6108(25)00117-5. International Cancer Proteogenome Consortium
PMID: 40185092

Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies Cancer Lett. 2025 Apr 1:614:217482. International Cancer Proteogenome Consortium
PMID: 39842500

Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment Nat Commun. 2024 Nov 23;15(1):10164. International Cancer Proteogenome Consortium
PMID: 39580524

A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights Nat Commun. 2024 Nov 22;15(1):10114. International Cancer Proteogenome Consortium
PMID: 39578447

Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance Exp Mol Med. 2024 Nov 1. doi: 10.1038/s12276-024-01332-w. International Cancer Proteogenome Consortium
PMID: 39482530

Multi-scale signaling and tumor evolution in high-grade gliomas Cancer Cell. 2024 Jul 8;42(7):1217-1238.e19. Clinical Proteomic Tumor Analysis Consortium
PMID: 38981438

Comprehensive proteogenomic characterization of rare kidney tumors Cell Rep Med. 2024 Apr 26:101547. Clinical Proteomic Tumor Analysis Consortium
PMID: 38703764

Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations Cancer Res. 2024 May 2;84(9):1491-1503. International Cancer Proteogenome Consortium
PMID: 38607364

Integrated proteogenomic characterization of glioblastoma evolution Cancer Cell. 2024 Jan 1:S1535-6108(23)00443-9. International Cancer Proteogenome Consortium
PMID: 38215747

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies Cell. 2024 Jan 4;187(1):184-203. International Cancer Proteogenome Consortium
PMID: 38181741

Proteomic-based stratification of intermediate-risk prostate cancer patients Life Sci Alliance. 2023 Dec 4;7(2):e202302146. International Cancer Proteogenome Consortium
PMID: 38052461

Proteogenomic insights suggest druggable pathways in endometrial carcinoma Cancer Cell. 2023 Sep 11;41(9):1586-1605.e15. Clinical Proteomic Tumor Analysis Consortium
PMID: 37567170

Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology Sci Transl Med. 2023 Jul 26;15(706) International Cancer Proteogenome Consortium
PMID: 37494474

Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects Gastroenterology. 2023 Jun;164(7):1293-1309 International Cancer Proteogenome Consortium
PMID: 36898552

Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes Nat Cancer. 2023 Feb;4(2):290-307 International Cancer Proteogenome Consortium
PMID: 36550235

Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness Cancer Cell. 2023 Jan 9;41(1):139-163 Clinical Proteomic Tumor Analysis Consortium
PMID: 36563681

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma Cancer Cell. 2021 Dec 28;S1535-6108(21)00659-0. International Cancer Proteogenome Consortium
PMID: 34971568

Proteogenomic characterization of pancreatic ductal adenocarcinoma Cell. 2021 Sep 16;184(19):5031-5052. Clinical Proteomic Tumor Analysis Consortium
PMID: 34534465

A proteogenomic portrait of lung squamous cell carcinoma Cell. 2021 Aug 5;184(16):4348-4371. Clinical Proteomic Tumor Analysis Consortium
PMID: 34358469

The human melanoma proteome atlas-Defining the molecular pathology Clin Transl Med. 2021 Jul;11(7):e473. International Cancer Proteogenome Consortium
PMID: 34323403

The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome Clin Transl Med. 2021 Jul;11(7):e451. International Cancer Proteogenome Consortium
PMID: 34323402

Proteogenomic and metabolomic characterization of human glioblastoma Cancer Cell. 2021 Apr 12;39(4):509-528. Clinical Proteomic Tumor Analysis Consortium
PMID: 33577785

Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma Cancer Cell. 2021 Jan 7;S1535-6108(20)30655-3. Clinical Proteomic Tumor Analysis Consortium
PMID: 33417831

Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer Cell. 2020 Dec 23;183(7):1962-1985.e31. Clinical Proteomic Tumor Analysis Consortium
PMID: 33242424

Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy Cell. 2020 Nov 25;183(5):1436-1456.e31. Clinical Proteomic Tumor Analysis Consortium
PMID: 33212010

Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma Cell Rep. 2020 Oct 20;33(3):108276. Clinical Proteomic Tumor Analysis Consortium
PMID: 33086064

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma Cell. 2020 Jul 9;182(1):200-225.e35. Clinical Proteomic Tumor Analysis Consortium
PMID: 32649874

Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression Cell. 2020 Jul 9;182(1):226-244.e17. International Cancer Proteogenome Consortium
PMID: 32649875

Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability Cell Rep Med. 2020 Apr 21;1(1):100004. Clinical Proteomic Tumor Analysis Consortium
PMID: 32529193

Proteogenomic Characterization of Endometrial Carcinoma Cell. 2020 Feb 20;180(4):729-748.e26. Clinical Proteomic Tumor Analysis Consortium
PMID: 32059776

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma Cell. 2019 Oct 31;179(4):964-983.e31. Clinical Proteomic Tumor Analysis Consortium
PMID: 31675502

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma Cell. 2019 Oct 3;179(2):561-577.e22. International Cancer Proteogenome Consortium
PMID: 31585088

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities Cell. 2019 May 2;177(4):1035-1049.e19. Clinical Proteomic Tumor Analysis Consortium
PMID: 31031003

Proteogenomic Characterization of Human Early-Onset Gastric Cancer Cancer Cell. 2019 Jan 14;35(1):111-124.e10. International Cancer Proteogenome Consortium
PMID: 30645970

APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism Nat Commun. 2017 Sep 6;8(1):465. International Cancer Proteogenome Consortium
PMID: 28878238

Publications